I tend to agree but it all depends on one's risk tolerance. Some investors may prefer a bit more of a cushion for their bet to not expire worthless, and are willing to pay a premium and/or cap profits for some added insurance.
I've made a fortune and lost a fortune in options. They're fun, exciting, and when executed properly can be a lower-cost way of taking advantage of quick volatility. But with a company like Anavex, my personal feeling is that post-approval it's going to take a bit of time to reach peak sales, probably at least 20-30 months. A lot of people will be skeptical until they either hear from multiple doctors or see firsthand through friends and family that Blarcamesine is safe and it works. I think there will be one cohort of population-eligible adults who end up starting their Blarcamesine regimen too late for maximum effect.
I am tempted to do some straddle options plays but I feel like for me, the best strategy is simply to buy and hold equity and clench my butt tightly until CHMP approval or rejection.
Market Data 
Markets 
AI
